Cardlytics filings document a Nasdaq-listed commerce media company's operating results, governance, capital structure, and material events. Form 8-K reports furnish quarterly and annual results, conference-call materials, cost-reduction actions, leadership and compensatory arrangements, and securities information for the company's common stock listed under CDLX.
The filing record also includes disclosure on the completed divestiture of Bridg, including the asset-sale closing and related unaudited pro forma financial statements. Proxy materials cover board matters, shareholder voting items, executive compensation, equity awards, and related governance disclosures for the company’s commerce media business.
Cardlytics, Inc. (CDLX) reported insider equity activity by Chief Executive Officer Amit Gupta. On August 16, 2026, Gupta acquired 25,000 shares of common stock upon the vesting and conversion of 25,000 Restricted Stock Units (RSUs), each RSU representing a contingent right to receive one share of common stock. These RSUs relate to two separate 50,000-share RSU awards granted on August 21, 2024 and January 29, 2025, which vest in four equal 25% installments over 24 months following August 16, 2024, subject to continued employment. On August 17–18, 2026, Gupta sold an aggregate of 13,461 shares of common stock in open-market or private transactions at weighted average prices of $3.966 and $4.031 per share, respectively. The filing’s Rule 10b5-1 checkbox indicates these sales were not made pursuant to a Rule 10b5-1 trading plan.
Cardlytics, Inc. (CDLX) is the issuer for a planned sale of common stock under Rule 144 by Amit Gupta. The notice covers up to 6,676 shares of common stock held at Fidelity Brokerage Services LLC, with a Rule 144 calculation reference price of $26,908.29 and an expiration date of August 18, 2026.
The shares to be sold arise from restricted stock vesting on August 14, 2026, characterized as a compensation-related transaction by the issuer. The filer notes that the sale includes an amount necessary to cover a tax obligation from the settlement of a vested equity award distribution.
The filing also lists sales of Cardlytics common stock by Amit Gupta during the prior three months: 6,498 shares on July 2, 2026 for $28,560.72, 9,640 shares on July 6, 2026 for $42,361.14, and 6,785 shares on August 17, 2026 for $26,908.63.
Amit Gupta filed a Form 144 indicating an intent to sell up to 6,785 shares of Cardlytics, Inc. (CDLX) common stock through Fidelity Brokerage Services LLC on or after 08/17/2026 on NASDAQ. The shares relate to restricted stock vesting on 08/14/2026 received as compensation. The filing also lists prior CDLX common stock sales in the last three months.
Cardlytics, Inc. reported Q2 2026 revenue of $36.9 million, down from $58.0 million a year earlier, as a U.S. financial-institution partner exited its platform and Monthly Qualified Users decreased. Continuing-operations net loss was $8.7 million and total net loss was $14.9 million.
The company completed the Bridg business sale, recording a $13.9 million gain in discontinued operations and later selling the 1.81 million PAR shares for $23.0 million, incurring a $2.4 million loss on investments. Cash and cash equivalents declined to $28.0 million, with $15.0 million drawn on a revolving credit facility and $172.5 million of 4.25% Convertible Senior Notes outstanding. Adjusted EBITDA was positive at $1.7 million in Q2, while stockholders’ equity stood at a $16.0 million deficit after a 1‑for‑10 reverse stock split reduced common shares outstanding to about 5.9 million.
Cardlytics, Inc. reported second quarter 2026 results showing lower activity but modest positive profitability on a non-GAAP basis. Revenue was $36.9 million, down 36% year-over-year, with billings of $65.5 million, down 34%. Adjusted Contribution was $21.3 million, down 32%, and Adjusted EBITDA was $1.7 million, compared with $3.0 million a year earlier.
The company recorded a net loss of $14.9 million versus $9.3 million in the prior-year quarter, or $(1.50) per share from continuing operations, and free cash flow of $(10.7) million. Monthly qualified users fell 17% to 185.4 million, while adjusted contribution per user declined to $0.11 from $0.14.
Cash and cash equivalents were $28.0 million as of June 30, 2026, with $169.4 million of convertible senior notes and $15.0 million outstanding on lines of credit, contributing to a stockholders’ deficit of $16.0 million. For the third quarter of 2026, Cardlytics guides to revenue of $34.0–$39.0 million, billings of $61.0–$67.0 million, adjusted contribution of $20.0–$23.0 million, and Adjusted EBITDA between $0 and $3.0 million, all lower year-over-year.
Cheng Christopher Chi-Kit reported acquisition or exercise transactions in this Form 4 filing.
Cardlytics, Inc. granted 50,000 Restricted Stock Units (RSUs) to Chief Legal & Privacy Officer Christopher Chi-Kit Cheng. Each RSU represents a contingent right to receive one share of Common Stock. The award vests over 24 months, with 25,000 units vesting on September 1, 2027 and the remainder vesting quarterly over the following 12 months, subject to continued employment. Following this grant, Cheng holds 50,000 RSUs directly.
Cardlytics, Inc. filed an initial insider ownership report for executive Christopher Chi-Kit Cheng, who serves as Chief Legal & Privacy Officer. The report identifies him as an officer of the company and, in this data set, shows no reportable stock transactions or derivative positions.
Cardlytics, Inc. director and CEO Amit Gupta reported a mix of RSU conversions and open-market sales of Common Stock. On July 1, 2026, he converted 18,750 and 12,500 Restricted Stock Units into the same number of Common Stock shares at a conversion price of $0.00 per share. On July 2, 2026 and July 6, 2026, he then sold 6,498 and 9,640 Common Stock shares, respectively, at weighted average prices of about $4.40 per share. Following these transactions, Gupta directly holds 113,850 Common Stock shares. The filing notes a 1-for-10 reverse stock split effective June 5, 2026, and explains that RSU awards continue to vest in scheduled quarterly installments through April 1, 2027 and April 1, 2028, subject to ongoing employment.
Cardlytics, Inc.’s Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer reported a combination of RSU vesting and a related share sale. On July 1, 2026, he exercised restricted stock units that delivered a total of 4,719 shares of Common Stock. On July 2, 2026, he sold 2,151 shares of Common Stock at a weighted average price of $4.395 per share, with footnotes stating the sale was made solely to cover tax withholding obligations from the RSU share delivery. Following these transactions, he directly holds 19,353 shares of Cardlytics common stock, with no remaining derivative positions shown in this filing.
Amit Gupta filed a Form 144 reporting proposed sales and recent dispositions of Common shares of CDLX. The filing lists 9,640 shares proposed to be sold on 07/02/2026 (listed as Restricted Stock Vesting / Compensation) and discloses prior dispositions of 69,833 shares on 04/06/2026 and 6,498 shares on 07/02/2026.